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Antimicrobial resistance is a relevant “One Health” issue that shows the
need of comparison of isolates of different origins. In this way, guidelines for
antimicrobial-resistance evaluation in animals are relevant in relation to human
sources. This work aims to compare antimicrobial-resistance results of animal
isolates considering CLSI and EUCAST guidelines. The comparison shows
considerable differences in the results, which include antibiotics used as primary
options in hospital infections. EUCAST showed the higher number of samples with
resistance profiles than CLSI that indicates a more efficient scenario to the
EUCAST to screen antibiotic-resistant bacteria. EUCAST was more consonant
to the expected phenotype for ESBL producers, with higher index of resistance to
oxyimino-beta-lactam antibiotics. The study shows that there are differences in the
interpretative results using different guidelines, where the susceptibility test results
concerning Enterobacteriaceae of animal origin are not always coincident in CLSI
and EUCAST. EUCAST has proved to be the most reliable alternative for profile
screening of antibiotic resistance, when compared to CLSI. We might say the same
with respect to the ESBL-producing Enterobacteriaceae, in which EUCAST has
proved to be more efficient about the demonstration of expected resistance profiles
for the ESBL producers. These differences show that guideline selection might
influence the therapeutic option.
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Introduction
Antibiotic resistance is a problem that has been going worse and worse in the
past decades. Therefore, detection and monitoring of the resistant microorganisms
and their mechanisms of resistance is of great importance. Antibiotic susceptibility is
evaluated using directions from notable institutions that are recognized by the
scientific community. The current leading institutions that supply these standards for
antibiotic susceptibility evaluation are the Clinical and Laboratory Standards
Institute (CLSI) fromNorth America and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) from Europe. The CLSI guidelines for Antibiotic
Susceptibility Tests (ASTs) were mostly used in the world for many years, given its
credibility (the Institute began as a National Committee – NCCLS –
almost 50 years ago) and were recognized in United States of America by Food
and Drug Administration. Laboratories need to pay an annual signature to have
access to the current version that is updated every year [1, 2]. The EUCAST has
been recognized at European level; it has been only 20 years and has emerged from
the unification of several European reference institutions, which justifies its
credibility and accessibility regarding the microbiology laboratories, once its content
is available for free [3, 4].
At present, there are no reference standards for AST interpretation con-
cerning microorganisms of animal origin in EUCAST. CLSI produces annually
the CLSI VET, which establishes criteria for samples of animal origin, that is
widely used in the United States [5]. However, for AST of bacteria of animal
origin, whether it is for animal prescription or for scientific research purposes, in
European reality, as for other countries, the human standard references of CLSI
and EUCAST are the most used [6–11].
Several studies have analyzed the differences and similarities of the results
obtained by the guidelines of both institutions regarding fungi and Gram-positive
and Gram-negative bacteria, yet the data related to the comparative evaluation of
results of Enterobacteriaceae from animal production are scarce and of great
importance to the comprehension of the differences that might exist between these
interpretations and their impact on resistance to antibiotics of the samples of
animal origin, which much concerns human health when analyzed by the
perspective of One Health [1, 12–18].
Materials and Methods
A range of 309 Enterobacteriaceae isolated from samples of healthy bovine
feces, of the production environment (manure, ration, and water consumed by the
414 PALMEIRA AND FERREIRA
Acta Microbiologica et Immunologica Hungarica 66, 2019
animals), and of other animal products (milk), were submitted to AST evaluation
by the agar diffusion method to 25 antimicrobials present on the interpretations by
this method in CLSI [19] and EUCAST [20]. Nitrofurantoin and fosfomycin were
analyzed only for Escherichia coli (266 strains). The samples from Brazilian
animal productions were obtained in April 2014. The obtained results were
classified as resistant, intermediate, or susceptible according to each institution.
The data were inserted into the SSPS software version 25 (IBM, USA), in which
the existent similarity between the obtained results by CLSI and EUCAST criteria
was interpreted. In addition, the “kappa” coefficient from the relationship between
results was analyzed to determine the relationship between both the results without
the influence of the statistic random. It is interpreted between “perfect agreement”
and “poor relationship.”
Results
The 25 antimicrobials analyzed showed differences varying between 99.4%
and 67.4%. Those that showed high percentage of similarity were: sulfamethoxa-
zole+ trimethoprim (99.4%), meropenem (98.4%), amoxicillin (97.7%),
imipenem (97.7%), netilmicin (97.6%), and fosfomycin and amikacin (96.7%).
Studies performed using the 2016 version of CLSI and EUCAST also showed
percentages of similarity above 95% for sulfamethoxazole+ trimethoprim and
meropenem [1]. Some antimicrobials showed low similarity values among the
obtained results: ceftaroline (67.4%), piperacillin+ tazobactam (73%), aztreonam
(76.3%), piperacillin (76.4%), and ciprofloxacin (76.6%). Table I shows similarity
values and “kappa” coefficient analysis for the 25 antimicrobials analyzed.
The “kappa” coefficient analysis results show that the results of no antimi-
crobial are in perfect agreement once no “kappa” coefficient 1 was obtained. The
best “kappa” coefficient results were classified as almost perfect regarding amoxi-
cillin – k of 0.952 (95% CI= 0.917, 0.987), cefoxitin – k of 0.844 (95% CI= 0.757,
0.930), amikacin – k of 0.819 (95% CI= 0.708, 0.929), sulfamethoxazole+
trimethoprim – k of 0.987 (95% CI= 0.969, 1.005), and chloramphenicol – k of
0.810 (95% CI= 0.730, 0.891). The classification “substantial” for the coefficient
“kappa” was the result that showed the biggest antimicrobials number, as amoxi-
cillin+ clavulanic acid – k of 0.609 (95% CI= 0.517, 0.700), piperacillin –
k of 0.612 (95% CI= 0.524, 0.700), cefuroxime – k of 0.676 (95% CI= 0.594,
0.758), cefotaxime k of 0.717 (95% CI= 0.632, 0.803), cefepime – k of 0.741 (95%
CI= 0.660, 0.822), meropenem – k of 0.661 (95% CI= 0.366, 0.956), imipenem –
k of 0.749 (95% CI= 0.565, 0.933), doripenem – k of 0.717 (95% CI= 0.594,
0.840), levofloxacin – k of 0.672 (95% CI= 0.579, 0.765), gentamicin – k of 0.766
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(95% CI= 0.651, 0.882), tobramycin – k of 0.684 (95% CI= 0.533, 0.835),
and netilmicin – k of 0.713 (95% CI= 0.465, 0.962). The results classified as
“moderate” are for ceftazidime – k of 0.439 (95% CI= 0.306, 0.573), ceftaroline –
k of 0.435 (95% CI= 0.336, 0.534), aztreonam – k of 0.460 (95% CI= 0.352,
0.568), ertapenem – k of 0.459 (95% CI= 0.261, 0.658), ciprofloxacin – k of
0.589 (95% CI= 0.506, 0.672), and fosfomycin – k of 0.561 (95% CI= 0.215,
0.908). Coefficient “kappa” results that showed the lowest classification, as
“fair” and “slight,” respectively, were piperacillin+ tazobactam – k of
0.292 (95% CI= 0.145, 0.439) and nitrofurantoin – k of 0.043 (95% CI=−0.227,
0.314).
When we compare the number of samples classified as resistant regarding
both the standards, we discover a scenario in which few results are coincident. Four
antibiotics (amoxicillin, amoxicillin+ clavulanic acid, amikacin, and sulfamethox-
azole+ trimethoprim) showed similar results to the resistance profile concerning
the susceptibility evaluation. In regard to five antibiotics (piperacillin+
tazobactam, cefotaxime, meropenem, imipenem, and nitrofurantoin), the CLSI
criteria showed more samples considered as resistant, when compared to
EUCAST, with emphasis on nitrofurantoin (CLSI – 4.4% and EUCAST –
0.5%). The other 16 antibiotics (piperacillin, cefuroxime, ceftazidime, cefepime,
ceftaroline, aztreonam, ertapenem, doripenem, ciprofloxacin, levofloxacin, genta-
micin, tobramycin, netilmicin, chloramphenicol, and fosfomycin) showed higher
number of resistant samples for EUCAST, presenting in some cases high
discrepancy, as for ceftaroline (EUCAST – 61.2% and CSLI – 28.7%), ciproflox-
acin (EUCAST – 46.1% and CLSI – 32.1%), and cefuroxime (EUCAST – 34.3%
and CLSI – 24.6%). Figure 1 presents the resistance profile for all 25 antibiotics,
concerning CLSI and EUCAST.
Among the 309 Enterobacteriaceae samples analyzed, 77 were extended-
spectrum beta-lactamase producers (ESBL), and when we look at their suscepti-
bility profile to third-, fourth-, and fifth-generation cephalosporins and to
monobactams, it is observed that there is a higher number of samples classified
as resistant (except for cefotaxime) in the EUCAST interpretation. This difference
is very clear for ceftazidime (EUCAST – 29.1% and CLSI – 12.7%), cefepime
(EUCAST – 53.2% and CLSI – 33.8%), and aztreonam (EUCAST – 29.9% and
CLSI – 15.6%), once the number of isolates with resistance profiles is superior to
the obtained by CLSI, and it might be the reason that masks the positive results of
AST of possible ESBL producers that do not show the typical synergism. This
resistance profile difference might show the hydrolytic strength for low-level beta-
lactamases, when CSLI is utilized. Figure 2 illustrates the comparative profiles
concerning the 77 ESBL-producing Enterobacteriaceae to the third-, fourth-, and
fifth-generation cephalosporins and to monobactams.
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Figure 1. Antibiotic resistance profile of Enterobacteriaceae strains according to CLSI (2017) and
EUCAST (2017) standards. AML: amoxicillin; AMC: amoxicillin+ clavulanic acid; PRL:
piperacillin; TZP: piperacillin+ tazobactam; CXM: cefuroxime; CTX: cefotaxime; CAZ:
ceftazidime; FEP: cefepime; CPT: ceftaroline; ATM: aztreonam; FOX: cefoxitin; ETP: ertapenem;
MRP: meropenem; IMI: imipenem; DOR: doripenem; CIP: ciprofloxacin; LEV: levofloxacin; CN:
gentamycin; TOB: tobramycin; AK: amikacin; NET: netilmicin; F: nitrofurantoin; SXT:
sulfamethoxazole+ trimetoprim; C: chloramphenicol; FOS: fosfomycin
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Discussion
The results showed significant differences about the profile of resistance of
Enterobacteriaceae of animal origin resistance when comparing CLSI and
EUCAST standards. Some evaluated antibiotics have obtained high similarity
according to Cohen’s classification, such as amoxicillin, cefoxitin, amikacin,
sulfamethoxazole+ trimethoprim, and chloramphenicol, classified as “almost
perfect.” Also showing good similarity, we can find amoxicillin+ clavulanic
acid, piperacillin, cefuroxime, cefotaxime, cefepime, meropenem, imipenem,
doripenem, levofloxacin, gentamicin, tobramycin, and netilmicin. However, six
antibiotics showed similar results classified only as “moderate,” such as ceftazi-
dime, ceftaroline, aztreonam, ertapenem, ciprofloxacin, and fosfomycin, which are
the antibiotics used as first options in hospital infections (ceftazidime and
aztreonam) and as alternative for infections caused by ESBL producers (cipro-
floxacin and fosfomycin). These differences show that the selection of the standard
might influence the therapeutic option [21, 22].
EUCAST showed the higher number of samples with resistance profiles
more prominent than CLSI. This fact indicates a scenario in which EUCAST
shows more efficient with respect to screening of the antibiotics resistance profile,
revealing a higher susceptibility in animal samples, when compared to CLSI,
given that for several antibiotics, EUCAST presented resistant samples, whereas in
the CLSI evaluation, those would be classified as susceptible or intermediate.
With regard to the ESBL producers, the EUCAST results have proved to be
more consonant to the expected phenotype for the Enterobacteriaceae that
Figure 2. Susceptibility profile of ESBL-producing Enterobacteriaceae to third-, fourth-, and
fifth-generation cephalosporins and to monobactams regarding CLSI (2017) and EUCAST (2017)
standards. CTX: cefotaxime; CAZ: ceftazidime; FEP: cefepime; CPT: ceftaroline; ATM: aztreonam
CLSI – EUCAST: FOR BACTERIA OF ANIMAL ORIGIN 419
Acta Microbiologica et Immunologica Hungarica 66, 2019
produces these enzymes, that is, higher index of resistance to third-, fourth-, and
fifth-generation cephalosporins and to aztreonam. A study performed with human
clinical samples has demonstrated that EUCAST is more efficient to the ESBL
detection [23].
Conclusions
The similarity of the susceptibility test results concerning Enterobacter-
iaceae of animal origin is not always coincident in CLSI and EUCAST, due to
different interpretations on the minimum inhibitory concentrations. Although
EUCAST has proved to be the most reliable alternative for profile screening of
resistance to antibiotics, once it has shown more efficient concerning detection of
resistance profiles by the agar diffusion method, when compared to CLSI. We
might say the same with respect to the ESBL-producing Enterobacteriaceae, in
which EUCAST has proved to be more efficient about the demonstration of
expected resistance profiles for the producers of these enzymes.
Acknowledgements
This work was supported by a scholarship of Coordination for the Improve-
ment of Higher Education Personnel (CAPES).
Conflict of Interest
The authors declare no competing interests.
References
1. Kassim, A., Omuse, G., Premji, Z., Revathi, G.: Comparison of Clinical Laboratory
Standards Institute and European Committee on Antimicrobial Susceptibility Testing
guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital
in Nairobi, Kenya: A cross-sectional study. Ann Clin Microbiol Antimicrob 15, 21 (2016).
2. Clinical and Laboratory Standards Institute (CLSI): CLSI Standards: Guidelines for Health
Care Excellence. CLSI, Wayne, PA, 2018.
3. Kahlmeter, G.: The 2014 Garrod Lecture: EUCAST –Are we heading towards international
agreement? J Antimicrob Chemother 70, 2427–2439 (2015).
4. European Committee on Antimicrobial Susceptibility Testing (EUCAST): Clinical
Breakpoints. EUCAST, 2018.
420 PALMEIRA AND FERREIRA
Acta Microbiologica et Immunologica Hungarica 66, 2019
5. Dargatz, D. A., Erdman, M. M., Harris, B.: A survey of methods used for antimicrobial
susceptibility testing in veterinary diagnostic laboratories in the United States. J Vet Diagn
Invest 29, 669–675 (2017).
6. Poirel, L., Nordmann, P., Ducroz, S., Boulouis, H.-J., Arné, P., Millemann, Y.: Extended-
spectrum β-lactamase CTX-M-15-producing Klebsiella pneumoniae of sequence type
ST274 in companion animals. Antimicrob Agents Chemother 57, 2372–2375 (2013).
7. Su, Y., Yu, C.-Y., Tsai, Y., Wang, S.-H., Lee, C., Chu, C.: Fluoroquinolone-resistant
and extended-spectrum β-lactamase-producing Escherichia coli from the milk of cows
with clinical mastitis in Southern Taiwan. J Microbiol Immunol Infect 49, 892–901
(2016).
8. Webb, H. E., Bugarel, M., den Bakker, H. C., Nightingale, K. K., Granier, S. A., Scott,
H. M., Loneragan, G. H.: Carbapenem-resistant bacteria recovered from faeces of dairy
cattle in the high plains region of the USA. PLoS One 11, e0147363 (2016).
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